eHealth, Inc.

GRI Bio, Inc.

Supernus Pharmaceuticals, Inc.

Eikon Therapeutics, Inc.

Candel Therapeutics, Inc.

Compass Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Cartesian Therapeutics, Inc.

Annovis Bio, Inc.

Dilution score: 27/100 (MEDIUM), 999.0 months cash

13F fund flow: neutral, 17 institutional managers

Citadel

Millennium

Point72

State Street

American Century

Neuberger Berman (Eisman)

Acadian

Renaissance Tech

Marshall Wace

DE Shaw

1768 PubMed publications found for eHealth, .

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.

How Digital Health Technologies have been Used to Support Regulatory Drug Approval.

Conversational mHealth Platform Designed to Support Tuberculosis Treatment Adherence in Low-Income South African Patients: Pilot Cohort Study.

Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Safety, Feasibility, and Patient Experience of Home-Based Chemotherapy.

Prescription patterns in the treatment of acutely ill seafarers over a three-year observation period.

Short interest: 2.76% of float, squeeze risk: LOW

SW convergence: 64/100 (Bullish Convergence), 1 bullish / 0 bearish signals

<article class="bts-verified-summary" data-ticker="EHTH">
<p>eHealth, Inc. (EHTH) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>EHTH has 2 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0001333493 (2026-06-17) <a href="https://efts.sec.gov/LATEST/search-index?q=%22EHTH%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-05-18&amp;enddt=2026-06-17" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR — 0001333493

eHealth, Inc. (EHTH) — BioTechSigns Verified Summary

eHealth, Inc. (EHTH) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

EHTH has 2 Form 4 insider filings recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0001333493. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://efts.sec.gov/LATEST/search-index?q=%22EHTH%22&forms=4&dateRange=custom&startdt=2026-05-18&enddt=2026-06-17